

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53441

Title: Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Reviewer's code: 03362724

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Germany

Manuscript submission date: 2019-12-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2019-12-30 16:20

Reviewer performed review: 2020-01-06 11:14

Review time: 6 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The manuscript is well organised and well studied about the change of podoplanin expression during neoadjuvant chemoradiation. I really appreciated the author for this novel finding.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53441

Title: Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Reviewer's code: 00182114

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: Germany

Manuscript submission date: 2019-12-30

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-07 01:09

Reviewer performed review: 2020-01-08 01:33

Review time: 1 Day

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is very interesting paper . Podoplanin is an oncofetal membrane protein, re-expressed in squamous cell carcinoma of the esophagus. I ask some questions to author. 1. Please tell me the reason why Podoplanin expressed squamous cell carcinoma of esophagus and did not express adenocarcinoma of the esophagus. Moreover, tell me the difference of carcinogenesis of squamous cell carcinoma and adenocarcinoma of esophagus. 2. According to author's data about Podoplanin scale, score 1 is 0-5%, score 2:6-35% and score 3: 36-65%. Please tell me the reason why stronger podoplanin protein expression is >5%. 3. According to Table 3, podoplanin did not show any significant relation to pT-category and lympho node metastasis. But Sonali Pradhau et al (Journal of applied oral science 2019) reported that the expression of podoplanin was associated with the degree of differentiation of the tumors. Please tell me the reason why podoplanin did not show any significant relation to pT-category and lympho node metastasis. 4. Please tell the tailored therapy for advanced esophageal cancer about Podoplanin.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 53441

Title: Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients

Reviewer's code: 00182114

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: Germany

Manuscript submission date: 2019-12-30

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-04-13 23:20

Reviewer performed review: 2020-04-15 00:25

Review time: 1 Day and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

This is very interesting paper. I ask some questions. 1. Please tell me the reason why Podoplanin is overexpressed in ESSS, but is not expressed in EADC. 2. Please tell me criteria of the cut off point in Podoplanin, low(0-5%),high (<5). 3. Please tell the etiology which chemoradiation reduced the level of Podoplanin. 4. Please tell me the result of chemoradiation in ESCC. How about good response, no change and bad response? 5. According to author's data, high level of Podoplanin is poor prognosis. I suspect Podoplanin inhibitor is good effect for the prognosis of ESCC. Please comment about Podoplanin inhibitor.